Autopsy report · NCT03234465
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Cause of deathFutility
“No efficacy could be demonstrated, sponsor decided to prematurely end the study.”
Life of this trial
- Ran for about 3 years before it stopped.
- 200 participants enrolled.
- Results were posted on the registry 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Oragenics, Inc.
- Sponsor type
- Industry
- Conditions
- Oral Mucositis
- Interventions
- AG013; Placebo
- Participants
- 200
- Sites
- 50
- Countries
- Belgium, Germany, United Kingdom, United States
Trials that died the same way
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome
“The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons.” - A Study of LY3405105 in Participants With Advanced Cancer
“The study was terminated for lack of sufficient efficacy.” - Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
“The study was terminated due to lack of efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
“Study stopped due to lack of efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.